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Nasal carriage of Staphylococcus pseudintermedius
in patients with granulomatosis with polyangiitis
Rheumatology key message
. Patients with granulomatosis with polyangiitis can
be colonized by Staphylococcus pseudintermedius,
with unclear contribution to disease pathogenesis.
SIR, granulomatosis with polyangiitis (GPA, formerly
Wegener’s granulomatosis) is characterized by necrotiz-
ing granulomatous inflammation usually involving the
upper and lower respiratory tract, and necrotizing vascu-
litis affecting predominantly small to medium vessels, fre-
quently leading to glomerulonephritis [1]. Disease
etiopathogenesis is complex but includes a genetic back-
ground, epigenetic modifications and environmental fac-
tors. There are several lines of evidence indicating an
association of nasal colonization with Staphylococcus
aureus and GPA. S. aureus is an independent risk factor
for relapse of GPA in carriers, and therapeutic administra-
tion of trimethoprim-sulfamethoxazole has been shown to
reduce relapse rates during a treatment period of 2 years
[2]. Little is known about other bacterial species that col-
onize the noses of GPA patients.
We undertook a study to investigate the bacterial spe-
cies carried by 69 patients with a diagnosis of GPA and
ENT involvement. This work was approved by the National
Research Ethics Service (NRES) Committee East of
England  Cambridge Central (REC reference: 08/
H0308/176). Informed consent was obtained before
sample collection. Nasal swabs (13 swabs per patient)
were inoculated into high-salt (7.5%) nutrient broths and
incubated statically at 37C overnight; from this culture,
100ml was inoculated onto Brilliance Staph 24 Agar (all
TABLE 1 Demographics of good and poor responders
Good responders, N=114 Poor responders, N=112
Age, mean (S.D.), years 55 (10) 52 (12)
% male 111 (98) 111 (98)
BMI, mean (S.D.), kg/m2 31.1 (5.0) 33.1 (5.9)
European, n (%) 89 (78.1) 86 (76.8)
Days on febuxostat prior to day 0, mean (S.D.) 46 (119) 32 (52)
Serum urate at day 0, mean (S.D.), mg/dl 4.1 (0.64) 6.3 (1.12)
ABCG2 rs2231142 allele count (freq.) GG/GT/TT 65 (0.57)/37 (0.32)/12 (0.11) 57 (0.51)/46(0.41)/9 (0.08)
ABCG2: ATP-binding cassette transporter G2.
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media sourced from Oxoid, UK). Representative blue
single colonies (putative S. aureus) were picked and
streaked to purity on Columbia blood agar for further ana-
lysis. We noted that swabs from two patients (referred
to as 0045 and 0093, neither with active disease in
the ENT tract when sampled) grew blue colonies (see
Supplementary Fig. S1AD, available at Rheumatology
online) identified as Staphylococcus pseudintermedius
by matrix-assisted laser desorption ionizationtime of
flight mass spectrometry (MALDI-TOF MS, Bruker,
Germany). Both were on immunosuppression (mycophe-
nolate mofetil and rituximab alongside steroids, respect-
ively) at the time of sampling (Supplementary Table S1,
available at Rheumatology online). Patient 0045 was posi-
tive for S. pseudintermedius on three occasions spaced
6 weeks apart (confirming persistent carriage), but we only
obtained a single swab from patient 0093.
Ten colonies from each of the primary culture plates
positive for S. pseudintermedius (30 colonies total for
0045 and 10 for 0093) were submitted for whole-
genome sequencing (Supplementary Table S2, available
at Rheumatology online). Ten colonies were picked from
each sample to determine whether the two participants
carried single or multiple S. pseudintermedius clones, as
previously reported for S. aureus [3]. Whole-genome se-
quence data confirmed the species identification.
Multilocus sequence typing derived from the sequence
data indicated that patient 0045 carried sequence type
(ST) 155 strain in all three samples (see Fig. 1a), and gen-
eration of a core genome phylogeny revealed that the 30
isolates differed by a total of 138 single-nucleotide poly-
morphisms across the core genome. Patient 0093 carried
a novel ST that was subsequently assigned as ST1025;
the 10 isolates from this patient differed by a total of 13
single-nucleotide polymorphisms (see Fig. 1b). All isolates
were genotypically methicillin susceptible on the basis of
being mecA negative. Isolates from patient 0045 con-
tained genes mediating resistance to penicillin (blaZ),
tetracycline (tetM) and aminoglycosides (aacA-aphD),
and 6 of 30 isolates tested from this case carried the tri-
methoprim-resistance gene dfrG (Fig. 1a). Isolates
from patient 0093 were positive for blaZ (penicillin resist-
ance) alone (Supplementary Table S2, available at
Rheumatology online).
S. pseudintermedius is a commensal and opportunistic
pathogen of cats and dogs, in which it causes skin and
soft tissue infections [4]. Increasingly, S. pseudintermedius
is recognized as a zoonosis in humans [5, 6]. Re-analysis
of isolates reported as S. aureus by clinical microbiology
laboratories may identify S. pseudintermedius in a small
proportion of patients [7]. A recent observational study at a
large regional microbiology laboratory over a 2-year period
reported the clinical characteristics of 24 patients who
were culture-positive for S. pseudintermedius [5]. Most
cases had severe co-morbidities and had contact with
dogs at the time of infection (92.1%). Isolates were
associated with skin and soft tissue infections in most
cases (75%), although two patients had invasive disease
[5]. This suggests that acquisition may occur from dogs,
FIG. 1 Multilocus sequence typing of both patients
Patient 0045 carried the ST155 strain in all three samples
(see Fig. 1a), and generation of a core genome phylogeny
revealed that the 30 isolates differed by a total of 138
SNPs across the core genome. Patient 0093 carried a
novel ST that was subsequently assigned as ST1025; the
10 isolates from this patient differed by a total of 13 SNPs
(see Fig. 1b). ST: sequence type; SNP: single nucleotide
polymorphisms.
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although a study that investigated the presence of
Staphylococcus spp. in 119 dogs and their 107 owners
found only one dogowner pair that both carried S. pseu-
dintermedius [8]. Neither patient in the present study had
a history of contact with dogs, and thus it remains
unclear which factors determine colonization with S.
pseudintermedius.
To the best of our knowledge, this is the first evidence of
persistent nasal carriage of S. pseudintermedius in humans.
The detection of two distinct lineages demonstrates that
colonization is not limited to a specific clone.
Transmission and factors leading to persistent carriage
are not known, but local damage relating to vasculitis and
pharmacological immune suppression may make GPA pa-
tients more prone to colonization. It remains unclear
whether S. pseudintermedius has any impact on relapse
risk or is directly involved in the etiopathogenesis of GPA.
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Coexistence of systemic lupus erythematosus with
Kikuchi-Fujimoto disease involving the salivary
gland, initially disguised as lymphoma
Rheumatology key message
. Kikuchi-Fujimoto disease associated with lupus can
mimic lymphoma due to nodal and extra-nodal
involvement.
SIR, Kikuchi-Fujimoto disease (KFD) is a histiocytic necro-
tizing lymphadenitis, which predominantly affects woman
of Japanese or other Asiatic descent aged 440 years [1].
The aetiology of KFD is not well established, but it is sus-
pected to be triggered by a virus or a hyper-autoimmune
response [2, 3]. It is a rare benign disease, characterized
by localized lymphadenopathy with fever and night
sweats. KFD is an important differential diagnosis for ma-
lignant lymphoma and other infectious conditions be-
cause it mimics their clinical presentation and laboratory
findings. Herein, we present the case of a male patient
with KFD showing salivary gland involvement, coexisting
with lupus, where lymphoproliferative disease was initially
suspected.
A 42-year-old otherwise healthy male presented to our
clinic with complaints of fever up to 38C for 3 weeks,
weight loss and night sweats. His medical history was
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